Status:

COMPLETED

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.

Lead Sponsor:

Mannkind Corporation

Conditions:

Ovarian

Melanoma

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a...

Detailed Description

The majority of tumors are ignored by the immune system and it was thought for a long time that tumor antigens did not exist. However, recently a number of tumor antigens have been described. These an...

Eligibility Criteria

Inclusion

  • 18 years of age or older Advanced, refractory solid malignancy that is histologically proven Measurable disease ECOG performance status of 0, 1 or 2 Adequate bone marrow reserve as evidenced by a Absolute neutrophil count (ANC) = 1,500/microL; Platelet count = 100,000/microL Adequate renal and hepatic function as evidenced by a serum creatinine = 1.5 mg/dL; Serum total bilirubin = 2.0 mg/dL; Alkaline phosphatase = 3X the ULN for the reference lab (= 5 the ULN for the reference lab for subjects with known hepatic metastases); SGOT/SGPT = 3X the ULN for the reference lab (= 5 the ULN for the reference lab for subjects with known hepatic metastases)

Exclusion

  • Symptomatic central nervous system (CNS) metastases Any autoimmune disorder Positive HIV, hepatitis B or hepatitis C antibody test Any allogeneic transplant Congestive heart failure Affected inguinal lymph nodes (metastatic process) or lack inguinal lymph nodes (resection)

Key Trial Info

Start Date :

February 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2009

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00423254

Start Date

February 1 2007

End Date

November 1 2009

Last Update

August 3 2010

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Arizona Cancer Center

Tuscon, Arizona, United States, 85724-5024

2

Lombardi Comprehensive Cancer Center at Georgetown

Washington D.C., District of Columbia, United States, 20057

3

H Lee Moffitt Cancer Center University of So Florida

Tampa, Florida, United States, 33612

4

Nevada Cancer Institute

Sparks, Nevada, United States, 89431